Table 1 Patient characteristics
Age at the enrollment (years, median [IQR]) | 22.5 [17.5 to 28.1] |
Female gender | 79.5% |
Age at the onset of primary disease (years, median [IQR]) | 10.6 [8.1 to 13.0] |
Primary diseases | |
SLE | 56.4% |
sJIA | 15.4% |
Others | 28.2% |
Age at the evaluation of osteoporosis (years, median [IQR]) | 12.0 [9.4 to 14.3] |
Age at the initiation of glucocorticoid therapy (years, median [IQR]) | 11.2 [8.2 to 13.2] |
Body weight at the initiation of glucocorticoid therapy (kg, median [IQR]) | 36.8 [24.2 to 43.0] |
Hospitalization during the study period | 100% |
Length of hospitalization during the study period (days, median [IQR]) | 85 [63 to 103] |
Length of the period between at the initiation of glucocorticoid therapy and evaluation of osteoporosis (years, median [IQR]) | 0.9 [0.7 to 1.1] |
Cumulative prednisolone-equivalent dose of glucocorticoids (mg, median [IQR]) | 12,043 [8790 to 14,213] |
Cumulative prednisolone-equivalent dose of glucocorticoids per body weight per day (mg/kg/day, median [IQR]) | 1.2 [0.8 to 1.5] |
Number of mPSLPT (median [IQR]) | 2 [1 to 2] |
Cumulative prednisolone-equivalent dose of glucocorticoids except mPSLPT (mg, median [IQR]) | 5881 [4606 to 7073] |
Cumulative prednisolone-equivalent dose of glucocorticoids per body weight per day except mPSLPT (mg/kg/day, median [IQR]) | 0.6 [0.5 to 0.8] |
Use of immunosuppressive drugsa | 76.9% |
Use of tocilizumab | 5.1% |
Supplementation of vitamin D | 38.5% |
Supplementation of calcium | 5.1% |
Alendronate therapy | |
before the enrollment | 79.5% |
Age at the initiation (years, median [IQR]) | 13.6 [10.0 to 15.5] |
Osteonecrosis of the jaw | 0% |
Other adverse effects | 0% |
before the evaluation of osteoporosis | 46.2% |
Age at the initiation (years, median [IQR]) | 11.5 [8.0 to 14.1] |
Osteonecrosis of the jaw | 0% |
Other adverse effects | 0% |
within 3 months after the initiation of glucocorticoid therapy | 30.8% |